Literature DB >> 33246599

Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).

Yunpeng Yang1, Hui Zhou2, Li Zhang3.   

Abstract

Entities:  

Year:  2020        PMID： 33246599     DOI： 10.1016/j.jtho.2020.09.028

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

Review 1.  Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.

Authors:  Yuan Cheng; Tao Zhang; Qing Xu
Journal:  MedComm (2020)       Date:  2021-12-14

2.  Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors.

Authors:  Nana Huang; Chenchen Zhao; Xueyang Hu; Congjun Zhang; Fuxing Xiong; Wei Huang; Liangshan Da; Yuanyuan Shen; Hongyang Wu
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

3.  Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases.

Authors:  Qian Shen; Jingjing Qu; Lingyan Sheng; Qiqi Gao; Jianying Zhou
Journal:  Front Oncol       Date:  2021-05-21       Impact factor: 6.244

4.  Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report.

Authors:  Zhilin Luo; Hong Zhang; Yajie Xiao; Rui Wang; Liping Zhang; Chenglu Huang; Yu Cao; Chao Sun; Yongtian Zhao; Hanqing Lin; Dongfang Wu; Tianhu Wang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

Review 5.  Research progress in immune checkpoint inhibitors for lung cancer in China.

Authors:  Jiadi Gan; Yihua Huang; Wenfeng Fang; Li Zhang
Journal:  Ther Adv Med Oncol       Date:  2021-07-20       Impact factor: 8.168
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.